Sign in to view content

Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy

Glenn J. Jaffe, MD

Video
Published 2022

Related

Characterizing Real-World Functional Outcomes in Patients with Geographic Atrophy: An IRIS Registry Analysis
Durga Borkar, MD
Annual Meeting Talks
2022
Episode 12: RPE Stem Cells for Dry AMD with Dr. Mark Humayun
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
Twelve Month Safety and Efficacy Outcomes from a Phase 2 Study of APL-2 in Patients with Geographic Atrophy
David S. Boyer, MD
Updates from the Field
2017

Category: AMD-Non-Neovascular

See more